SCHEMBL16385239

SCHEMBL16385239

Cc1cc(-c2cc(Cl)ccn2)ccc1O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 3/20 0.57
ESR2 Q92731 2/20 0.56
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
HSD17B1 P14061 5/20 0.43
HSD17B2 P37059 5/20 0.43
PIM1 P11309 2/20 0.41
HSD17B14 Q9BPX1 1/20 0.41
CDC7 O00311 1/20 0.40
CSNK2A2 P19784 1/20 0.40
CLK1 P49759 1/20 0.40
GSK3B P49841 1/20 0.40
CSNK2B P67870 1/20 0.40
CSNK2A1 P68400 1/20 0.40
CSNK2A3 Q8NEV1 1/20 0.40
MAPT P10636 1/20 0.39
NPC1 O15118 1/20 0.39
GAA P10253 1/20 0.39
RAB9A P51151 1/20 0.39
FGFR1 P11362 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9202204 0.84 ALOX5 (0.52) TLR8ESR2MEN1KMT2AMAPT
SCHEMBL16385302 0.83 CCR1 (0.55) TLR8ESR2MEN1KMT2AHSD17B1
SCHEMBL16385278 0.78 MAPT (0.48) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL5700322 0.77 PIK3CG (0.50) MEN1KMT2APIM1MAPT
SCHEMBL16385303 0.77 HSD17B1 (0.52) TLR8ESR2MEN1KMT2AHSD17B1
SCHEMBL172718 0.76 HSD17B1 (0.51) TLR8ESR2HSD17B1HSD17B2PIM1
Bromide SCHEMBL17744696 0.75 HSD17B1 (0.50) TLR8ESR2HSD17B1HSD17B2PIM1
SCHEMBL16385300 0.75 HSD17B1 (0.47) TLR8ESR2HSD17B1HSD17B2PIM1
SCHEMBL17788166 0.75 KDM4E (0.53) TLR8ESR2MEN1KMT2AHSD17B1
SCHEMBL23496987 0.73 TLR8 (1.00) TLR8ESR2MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3020715-B1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2021-06-16 EP disclosed
US-9888688-B2 Tetrazolinone compounds and applications thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-02-13 US disclosed
US-9888688-B2 Tetrazolinone compounds and applications thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-02-13 US disclosed
US-20160150787-A1 TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-06-02 US disclosed
US-20160150787-A1 TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-06-02 US disclosed
WO-2015005499-A1 TETRAZOLINONE COMPOUND AND USE THEREOF 住友化学株式会社 (JP) 2015-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160150787-A1 TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF SOD1, UQCRB, MT-CO1 TLR8 2871/4885ESR2 2385/4885MEN1 3183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.